Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Background G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …

Background Survival is poor among patients with triple-class–exposed relapsed and
refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Abstract IgG4-related disease (IgG4-RD) has only existed as a unique disease entity since
2003, yet remarkable progress has already been achieved in describing the essential …

Summary This Policy Review presents the International Myeloma Working Group's clinical
practice recommendations for the treatment of relapsed and refractory multiple myeloma …

Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Summary Systemic Lupus Erythematosus (SLE) is characterized by B cells lacking IgD and
CD27 (double negative; DN). We show that DN cell expansions reflected a subset of CXCR5 …

Background The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide
and dexamethasone has been shown to be effective in patients with relapsed or refractory …